Table 3.
Unadjusted Rate of Physician-Reported Adherence to Recommendations Against Ovarian Cancer Screening by Patient, Physician, and Practice Characteristics
| All physicians (n = 497) | |
|---|---|
| Total | 71.8 |
| Patient characteristics | |
| Age (years) | |
| 35 | 72.4 |
| 51 | 71.3 |
| Race | |
| African American | 72.6 |
| Caucasian | 70.1 |
| Insurance typea | |
| Private | 67.8 |
| Medicaid | 76.5 |
| Requested ovarian cancer screeningb | |
| Yes | 63.9 |
| No | 79.7 |
| Physician and practice characteristics | |
| Age (years) | |
| 30–39 | 78.7 |
| 40–49 | 73.4 |
| 50–64 | 66.7 |
| Sex | |
| Female | 73.8 |
| Male | 70.4 |
| Specialtyc | |
| Family medicine | 72.8 |
| Obstetrics-gynecology | 60.5 |
| General internal medicine | 76.0 |
| Board certification | |
| Yes | 73.1 |
| No | 58.3 |
| Years in practice | |
| 0–10 | 75.2 |
| 11–20 | 72.7 |
| 21+ | 69.6 |
| Practice typeb | |
| Solo practice | 57.4 |
| Group practice or other practice type | 76.3 |
| Weekly average number of patients | |
| 1–60 | 76.9 |
| 61–90 | 75.6 |
| 91+ | 65.5 |
| Involved in clinical teaching | |
| Yes | 72.9 |
| No | 70.8 |
| Geographic location | |
| Small rural/remote rural | 66.8 |
| Large rural | 69.0 |
| Urban | 72.6 |
| Census division | |
| New England | 59.5 |
| Middle Atlantic | 65.5 |
| East North Central | 80.8 |
| West North Central | 67.8 |
| South Atlantic | 76.2 |
| East South Central | 68.0 |
| West South Central | 63.4 |
| Mountain | 64.2 |
| Pacific | 77.0 |
| Level of risk taking | |
| Low (6–17) | 71.8 |
| Medium (18–24) | 71.7 |
| High (25+) | 71.8 |
| Fear of malpractice | |
| Low (2–4) | 73.5 |
| Medium (5–7) | 77.2 |
| High (8+) | 68.8 |
| USPSTF among top three sources of cancer screening informationb | |
| Yes | 79.6 |
| No | 623 |
| NIH/NCI among top three sources of cancer screening informationa | |
| Yes | 65.9 |
| No | 75.0 |
| ACOG among top three sources of cancer screening information | |
| Yes | 67.4 |
| No | 73.9 |
| ACS among top three sources of cancer screening information | |
| Yes | 70.6 |
| No | 74.0 |
| TVU is clinically effective in screening for ovarian cancerb | |
| Agree | 48.1 |
| Disagree | 81.0 |
| CA125 is clinically effective in screening for ovarian cancerb | |
| Agree | 40.2 |
| Disagree | 79.3 |
| Either TVU or CA125 is clinically effective in screening for ovarian cancerb | |
| Agree | 47.7 |
| Disagree | 82.9 |
p ≤ 0.05
p ≤ 0.001
p ≤ 0.01.
Results were adjusted using weights to represent the specialty distribution of the practicing U.S. physician population of family physicians, general internists, and obstetrician-gynecologists.